Irritable Bowel Syndrome (IBD)

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 74 36 42 43 15 62 17 71 32
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12


External Ids:

Disease Ontology 12 DOID:9778
KEGG 36 H01615
ICD9CM 34 564.1
MeSH 43 D043183
NCIt 49 C82343
SNOMED-CT 67 10743008
ICD10 32 K58 K58.0 K58.9
UMLS 71 C0022104

Summaries for Irritable Bowel Syndrome

KEGG : 36 Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to cholangitis, primary sclerosing and cyclic vomiting syndrome, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Irritable Bowel Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Peptide ligand-binding receptors. The drugs Pentoxifylline and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An intestinal disease that is characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

MedlinePlus : 42 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

PubMed Health : 62 About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 74 Irritable bowel syndrome (IBS) is a group of symptoms—including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 905)
# Related Disease Score Top Affiliating Genes
1 cholangitis, primary sclerosing 33.5 TNF TLR4 IL6 IL10
2 cyclic vomiting syndrome 33.3 IL6 HTR3A
3 fibromyalgia 33.1 TNF SLC6A4 IL6 IL1B IL10 HTR3A
4 interstitial cystitis 33.1 TRPV1 TAC1 IL6
5 depression 31.9 TPH1 SLC6A4 CRHR1 CRH
6 diarrhea 31.9 TRPV1 TPH1 TNF TLR4 TGM2 TAC1
7 gastroenteritis 31.9 TNF PYY MLN IL6 IL1B IL10
8 microscopic colitis 31.8 TNF TGM2 SLC6A4 IL6
9 ulcerative colitis 31.8 TNF TLR4 IL6 IL1B IL10
10 colitis 31.8 TNF TLR4 IL6 IL1B IL10
11 food allergy 31.7 TNF TLR4 IL10
12 generalized anxiety disorder 31.7 TPH1 SLC6A4 HTR3A CRHR1
13 crohn's disease 31.6 TNF TLR4 IL6 IL1B IL10
14 sclerosing cholangitis 31.6 TNF TLR4 IL6 IL10
15 cholangitis 31.6 TNF TLR4 IL6 IL10
16 acute stress disorder 31.5 SLC6A4 CRHR1 CRH
17 celiac disease 1 31.5 TNF TLR4 TGM2 PYY IL6 IL1B
18 dysentery 31.5 TNF TLR4 IL6 IL1B IL10
19 lymphocytic colitis 31.4 TNF TGM2 PYY
20 mood disorder 31.4 TPH1 SLC6A4 IL6 HTR3A CRHR2 CRHR1
21 sleep disorder 31.4 TNF SLC6A4 IL6 IL1B
22 constipation 31.4 VIP TRPV1 TPH1 TNF TGM2 TAC1
23 somatization disorder 31.4 TAC1 SLC6A4 CRH
24 peptic ulcer disease 31.4 TNF IL1B IL10
25 gastroesophageal reflux 31.4 VIP TNF PYY MLN IL6 IL1B
26 neurotic disorder 31.4 TNF SLC6A4 IL6
27 eating disorder 31.3 SLC6A4 PYY CRHR2 CRH CCK
28 inflammatory bowel disease 31.3 VIP TNF TLR4 TAC1 PYY IL6
29 post-traumatic stress disorder 31.3 SLC6A4 IL1B CRHR1 CRH
30 chickenpox 31.3 TNF IL6 IL10
31 spondylitis 31.2 TNF IL6 IL10
32 gastrointestinal system disease 31.2 MLN MIR24-1 HTR4 CCK
33 alcohol use disorder 31.2 SLC6A4 HTR3A CRHR1 CRH
34 dermatitis 31.2 TNF IL6 IL1B IL10
35 prostatitis 31.1 TNF IL6 IL1B IL10
36 esophagitis 31.1 TNF MLN IL6 IL1B IL10
37 phobic disorder 31.1 SLC6A4 CRHR1 CRH
38 gastroparesis 31.1 MLN HTR3A CCK
39 social phobia 31.1 SLC6A4 HTR3A CCK
40 neutropenia 31.1 TNF TLR4 IL6 IL1B IL10
41 proteasome-associated autoinflammatory syndrome 1 31.1 TNF TLR4 IL6 IL1B IL10
42 duodenogastric reflux 31.1 PYY MLN CCK
43 chronic fatigue syndrome 31.1 TNF TLR4 SLC6A4 IL6 IL1B IL10
44 gastritis 31.1 TNF TLR4 IL6 IL1B IL10
45 shigellosis 31.1 TNF TLR4 IL1B IL10
46 uveitis 31.1 TNF IL6 IL1B IL10
47 amebiasis 31.1 TNF TLR4 IL1B
48 herpes zoster 31.0 TRPV1 TNF IL10
49 bacterial infectious disease 31.0 TNF TLR4 IL6 IL1B IL10
50 exanthem 31.0 TNF IL6 IL1B IL10

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 24)

Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Deficiency Anemia Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:

Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:

nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, vomiting following gastrointestinal surgery

MGI Mouse Phenotypes related to Irritable Bowel Syndrome:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 CRH CRHR1 CRHR2 HTR3A HTR4 IL10
2 homeostasis/metabolism MP:0005376 10.36 CCK CRH CRHR1 CRHR2 HTR3A HTR4
3 cardiovascular system MP:0005385 10.31 CRHR1 CRHR2 IL10 IL1B IL6 SLC6A4
4 growth/size/body region MP:0005378 10.27 CRH HTR3A HTR4 IL10 IL1B IL6
5 endocrine/exocrine gland MP:0005379 10.26 CCK CRH CRHR1 CRHR2 HTR3A IL10
6 adipose tissue MP:0005375 10.18 CRH CRHR2 HTR4 IL6 PYY TLR4
7 immune system MP:0005387 10.14 CRH CRHR2 HTR3A IL10 IL1B IL6
8 integument MP:0010771 10.11 CRH HTR3A IL10 IL1B IL6 SLC6A4
9 nervous system MP:0003631 10.1 CCK CRH CRHR1 HTR3A HTR4 IL10
10 neoplasm MP:0002006 9.87 IL10 IL1B IL6 TGM2 TLR4 TNF
11 no phenotypic analysis MP:0003012 9.7 CCK CRH CRHR1 IL10 TGM2 TNF
12 renal/urinary system MP:0005367 9.56 CCK CRH HTR3A IL6 TAC1 TGM2
13 respiratory system MP:0005388 9.28 CRH CRHR1 HTR4 IL10 IL6 TLR4

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMed Health treatment related to Irritable Bowel Syndrome: 62

There are a lot of different opinions about what can help relieve irritable bowel syndrome . Common recommendations include eating or avoiding certain foods and getting exercise . But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps. For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while. There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include: Fiber supplements, for instance made from psyllium Peppermint oil Probiotics Anti-cramping medications Medications for constipation or diarrhea Various medications, such as antibiotics or antidepressants Psychological treatments , such as stress management or hypnosis Because medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
Turmeric Approved, Experimental, Investigational Phase 4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Alverine Approved, Investigational Phase 4 150-59-4 3678
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
Histamine Approved, Investigational Phase 4 51-45-6 774
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
Trimebutine Approved Phase 4 39133-31-8
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Ondansetron Approved Phase 4 99614-02-5 4595
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
Secretin Approved Phase 4 108153-74-8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
Dienogest Approved Phase 4 65928-58-7
Drospirenone Approved Phase 4 67392-87-4 68873
Lactulose Approved Phase 4 4618-18-2 11333
Ferrous fumarate Approved Phase 4 141-01-5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Norethindrone Approved Phase 4 68-22-4 6230
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Polyestradiol phosphate Approved Phase 4 28014-46-2
Colestipol Approved Phase 4 26658-42-4
Ethanol Approved Phase 4 64-17-5 702
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Linaclotide Approved Phase 4 851199-59-2 65351
Citalopram Approved Phase 4 59729-33-8 2771
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Tiropramide Investigational Phase 4 55837-29-1 42262
Rebamipide Investigational Phase 4 90098-04-7
Ramosetron Investigational Phase 4 132036-88-5
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
40 Fenoverine Investigational Phase 4 37561-27-6
Genistein Investigational Phase 4 446-72-0 5280961
Daidzein Experimental Phase 4 486-66-8 5281708
43 Guar Phase 4
44 Phosphodiesterase Inhibitors Phase 4
45 Antioxidants Phase 4
46 Platelet Aggregation Inhibitors Phase 4
47 Vasodilator Agents Phase 4
48 Radiation-Protective Agents Phase 4
49 Protective Agents Phase 4
50 Cyclooxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 912)
# Name Status NCT ID Phase Drugs
1 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
2 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
3 Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
4 Peripheral Histamine 1 Receptor Blockade in IBS Unknown status NCT01908465 Phase 4 Ebastine;Placebo
5 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
6 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
7 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
8 Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
9 Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo Unknown status NCT02573844 Phase 4 Proklama
10 Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
11 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
12 Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
13 Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery Unknown status NCT02849483 Phase 4 Ramosetron;Normal saline
14 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
15 Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome Unknown status NCT03557788 Phase 4 Rifaximin Oral Tablet
16 Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study Unknown status NCT02508142 Phase 4 Hyoscine-N-Butylbromide
17 Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema) Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
18 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
19 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
20 Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
21 A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects Completed NCT00370032 Phase 4 alosetron
22 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT01225237 Phase 4 Ramosetron;Placebo
23 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
24 Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
25 3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM) Completed NCT03441581 Phase 4 Eluxadoline
26 Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
27 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
28 IBS Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
29 Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
30 Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D). Completed NCT01316718 Phase 4 Mesalazine;Placebo
31 Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language) Completed NCT02077699 Phase 4
32 A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF) Completed NCT02959983 Phase 4 Eluxadoline;Placebo
33 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
34 An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. Completed NCT02590432 Phase 4 Linaclotide
35 Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study. Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
36 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
37 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
38 Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial Completed NCT01507922 Phase 4 Fenoverine;Timebutine
39 Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome Completed NCT02111603 Phase 4 Colesevelam
40 Efficacy of the Combination Therapy With Alverine-simeticone and i3.1 Probiotic Formula in the Quality of Life of Patients With IBS-D or IBS-M in Hospital Juarez Mexico Completed NCT04145856 Phase 4
41 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
42 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
43 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
44 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder" Completed NCT00745004 Phase 4 Ondansetron;Placebo
45 Supplementation With a Multi-strain Probiotic Formulation (Bio-Kult®) in the Management of Diarrhea-predominant Irritable Bowel Syndrome - a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT03251625 Phase 4 Probiotic Formula Capsule
46 Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
47 Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation Completed NCT01331213 Phase 4 Pregabalin;Placebo
48 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
49 Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial Completed NCT01495806 Phase 4 Glucomannan;placebo
50 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

alosetron hydrochloride
calcium polycarbophil
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Propantheline Bromide
Tegaserod maleate

Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

Colon, Testes, Brain, Small Intestine, Liver, Spinal Cord, Kidney

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 12712)
# Title Authors PMID Year
Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life. 42 61
32384473 2020
Drugs for Irritable Bowel Syndrome. 61 42
32324172 2020
5-Aminosalicylic acid for treatment of irritable bowel syndrome: A protocol for a systematic review and meta-analysis. 61 42
32118774 2020
Evaluation of the effects of Bidens tripartita extracts and their main constituents on intestinal motility - An ex vivo study. 61
32442590 2020
Ghrelin acts in the brain to block colonic hyperpermeability in response to lipopolysaccharide through the vagus nerve. 61
32442542 2020
Variability in yeast invertase activity determines the extent of fructan hydrolysis during wheat dough fermentation and final FODMAP levels in bread. 61
32387971 2020
Bacterial therapy for irritable bowel syndrome. 61
32277873 2020
Monocyte chemotactic protein-1 and nitrotyrosine in irritable bowel syndrome. 61
32508988 2020
Burnout, but not job strain, is associated with irritable bowel syndrome in working adults. 61
32371342 2020
Adherence to Short-course Pharmacotherapy in Adults with Irritable Bowel Syndrome. 61
31441709 2020
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. 61
32277872 2020
Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity. 61
32417626 2020
microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB. 61
32187820 2020
Associations of Abdominal Pain and Psychosocial Distress Measures With Health-Related Quality-of-Life in Pediatric Healthy Controls and Irritable Bowel Syndrome. 61
32554991 2020
Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives. 61
32538776 2020
Parasitic infections in irritable bowel syndrome patients: evidence to propose a possible link, based on a case-control study in the south of Iran. 61
32487206 2020
Altered resting-state functional connectivity and effective connectivity of the habenula in irritable bowel syndrome: A cross-sectional and machine learning study. 61
32488929 2020
Electroacupuncture relieves irritable bowel syndrome by increasing expression of nucleotide-binding oligomerization domain protein-like receptor family pyrin domain containing 6 in water-avoidance stress mice. 61
32506854 2020
The association of different interoceptive dimensions with functional gastrointestinal symptoms. 61
32538172 2020
Predictors of new onsets of irritable bowel syndrome, chronic fatigue syndrome and fibromyalgia: the lifelines study. 61
32546287 2020
Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome: A case-control study. 61
32502027 2020
Electrocolonography: Non-Invasive Detection of Colonic Cyclic Motor Activity From Multielectrode Body Surface Recordings. 61
31535980 2020
[Unique characteristics of "the second brain" - The enteric nervous system]. 61
32572435 2020
Application of metabolomics to the study of irritable bowel syndrome. 61
32426922 2020
Pharmacologic Treatments for Irritable Bowel Syndrome: an Umbrella Systematic Review. 61
32530987 2020
Tenapanor for the treatment of irritable bowel syndrome with constipation. 61
32478632 2020
Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation. 61
32569031 2020
Chronic Constipation in the United States: Results From a Population-Based Survey Assessing Healthcare Seeking and Use of Pharmacotherapy. 61
32324606 2020
An invited commentary on "The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials" [Int. J. Surg. 79 (2020) 111-119]. 61
32544546 2020
The Impact of an Individual Educational Program on the Quality of Life and Severity of Symptoms of Patients with Irritable Bowel Syndrome. 61
32545800 2020
Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial. 61
32499125 2020
Irritable bowel syndrome: diagnosis and management. 61
31820883 2020
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis. 61
32406112 2020
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. 61
32343000 2020
Letter: balancing gut hydrogen as a proxy for bacteriotherapy benefits in irritable bowel syndrome. 61
32445528 2020
Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome. 61
32056324 2020
Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. 61
32558017 2020
Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. 61
32531003 2020
No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. 61
31601615 2020
Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms. 61
32555219 2020
Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action. 61
32530990 2020
Skills over pills? A clinical gastroenterologist's primer in cognitive behavioral therapy for irritable bowel syndrome. 61
32510249 2020
Quality of life and psychometric evaluation of patients diagnosed with irritable bowel syndrome: an observational cohort study. 61
32556060 2020
An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. 61
32380874 2020
Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. 61
32536023 2020
β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. 61
32433273 2020
Functional dyspepsia is associated with lower exercise levels: A population-based study. 61
32228173 2020
Irritable bowel syndrome increases the risk of chronic obstructive pulmonary disease: A retrospective cohort study. 61
32561774 2020
Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders. 61
32339805 2020
Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. 61
32517023 2020

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

Pathways related to Irritable Bowel Syndrome according to KEGG:

# Name Kegg Source Accession
1 Inflammatory bowel disease (IBD) hsa05321

Pathways related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
12.57 TNF TLR4 IL6 IL1B IL10
Show member pathways
12.56 TNF TLR4 IL6 IL1B IL10
Show member pathways
12.29 TNF TLR4 IL6 IL1B
6 12.29 TNF TLR4 IL6 IL1B
7 12.25 TNF TLR4 IL6 IL1B
Show member pathways
12.24 TNF TLR4 IL1B IL10
9 12.21 TNF TLR4 IL6 IL1B
10 12.2 TNF TLR4 IL6 IL1B IL10
Show member pathways
12.19 TNF IL6 IL1B IL10
Show member pathways
12.17 TNF TLR4 IL6 IL1B
14 11.99 TNF TLR4 IL6 IL1B
15 11.97 TNF TLR4 IL6 IL1B IL10
16 11.96 TPH1 SLC6A4 HTR4 HTR3A
17 11.95 TNF IL6 IL1B IL10
Show member pathways
11.86 TNF TLR4 IL6 IL1B IL10
19 11.85 TNF TLR4 IL6 IL1B
20 11.85 TLR4 CRHR2 CRHR1 CRH
21 11.81 TNF TLR4 IL6 IL1B IL10
22 11.76 TNF IL1B IL10
23 11.73 TNF IL6 IL1B IL10
Show member pathways
11.65 TNF IL6 IL1B
25 11.64 TNF IL6 IL1B
26 11.59 TNF TLR4 IL6 IL1B
27 11.54 TNF TLR4 IL6 IL1B IL10
28 11.5 TNF TLR4 IL1B
29 11.5 TNF IL6 IL1B IL10
30 11.47 TNF IL6 IL1B
Show member pathways
11.43 TNF SLC6A4 IL1B
32 11.43 TPH1 TNF TAC1 SLC6A4 IL6 IL1B
33 11.33 TNF IL6 IL1B IL10
34 11.3 TNF IL6 IL1B
35 11.27 TNF IL6 IL1B
36 11.25 TNF TLR4 IL6 IL1B IL10
37 11.13 TNF IL6 IL1B IL10
38 11.07 TPH1 SLC6A4 HTR4 HTR3A
39 10.9 TNF TLR4 IL6 IL1B IL10
40 10.76 IL6 IL1B
41 10.51 VIP CCK
42 10.5 CRHR2 CRHR1 CRH

GO Terms for Irritable Bowel Syndrome

Cellular components related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 VIP TNF TAC1 PYY MLN IL6
2 integral component of plasma membrane GO:0005887 9.92 TRPV1 TNF TLR4 SLC6A4 HTR4 HTR3A
3 synapse GO:0045202 9.88 TRPV1 TAC1 SLC6A4 HTR4 HTR3A CRH
4 extracellular space GO:0005615 9.81 TNF TAC1 PYY MIR24-1 IL6 IL1B
5 neuronal cell body GO:0043025 9.77 TRPV1 TAC1 HTR3A CRH CCK
6 neuron projection GO:0043005 9.43 VIP TRPV1 TPH1 SLC6A4 HTR3A CRHR1
7 intrinsic component of plasma membrane GO:0031226 8.92 TRPV1 TLR4 TGM2 CRHR1

Biological processes related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.06 TRPV1 TNF TGM2 IL6 CCK
2 immune response GO:0006955 10.05 TNF TLR4 IL6 IL1B IL10 CRHR1
3 positive regulation of gene expression GO:0010628 10.03 TNF TLR4 SLC6A4 IL6 IL1B CRH
4 chemical synaptic transmission GO:0007268 10.01 TAC1 HTR4 HTR3A CRH
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.97 TNF TLR4 TGM2 IL1B
6 response to lipopolysaccharide GO:0032496 9.97 TLR4 TAC1 IL1B IL10
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF TLR4 IL6 IL1B
8 G protein-coupled receptor signaling pathway GO:0007186 9.91 VIP TAC1 PYY MLN HTR4 CRHR2
9 signal transduction GO:0007165 9.9 VIP TLR4 IL6 IL1B IL10 HTR4
10 positive regulation of JNK cascade GO:0046330 9.88 TNF TLR4 IL1B
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF IL6 IL1B IL10
12 response to glucocorticoid GO:0051384 9.87 TNF IL6 IL10
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 TNF TLR4 IL1B
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 TNF TGM2 IL6
15 positive regulation of interferon-gamma production GO:0032729 9.82 TNF TLR4 IL1B
16 positive regulation of interleukin-6 secretion GO:2000778 9.81 TNF TLR4 IL1B
17 positive regulation of inflammatory response GO:0050729 9.81 TNF TLR4 TGM2 IL1B
18 negative regulation of interleukin-6 production GO:0032715 9.8 TNF TLR4 IL10
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 IL1B
20 cellular response to lipopolysaccharide GO:0071222 9.8 TNF TLR4 IL6 IL1B IL10
21 regulation of sensory perception of pain GO:0051930 9.77 VIP IL10 CCK
22 positive regulation of JAK-STAT cascade GO:0046427 9.77 TNF IL6 IL10
23 positive regulation of interleukin-8 production GO:0032757 9.74 TNF TLR4 IL1B
24 negative regulation of neurogenesis GO:0050768 9.72 TNF IL6 IL1B
25 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.71 TNF TLR4
26 negative regulation of heart rate GO:0010459 9.71 TRPV1 TAC1
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 TLR4 IL10
28 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
29 parturition GO:0007567 9.7 CRHR1 CRH
30 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.7 TNF TLR4 IL6
31 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
32 endothelial cell apoptotic process GO:0072577 9.69 TNF IL10
33 positive regulation of lymphocyte proliferation GO:0050671 9.68 TLR4 TAC1
34 positive regulation of behavioral fear response GO:2000987 9.68 CRH CCK
35 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
36 response to pain GO:0048265 9.67 TRPV1 TAC1 CRH
37 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.66 CRHR2 CRHR1
38 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
39 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
40 positive regulation of chemokine production GO:0032722 9.65 TNF TLR4 IL6
41 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
42 positive regulation of glial cell proliferation GO:0060252 9.63 TNF IL6 IL1B
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 TNF IL1B
44 positive regulation of interleukin-6 production GO:0032755 9.62 TNF TLR4 IL6 IL1B
45 receptor biosynthetic process GO:0032800 9.61 TNF IL10
46 fever generation GO:0001660 9.61 TRPV1 IL1B
47 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 TNF IL1B IL10
48 positive regulation of corticosterone secretion GO:2000854 9.54 TAC1 CRH
49 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
50 positive regulation of nitric oxide biosynthetic process GO:0045429 9.26 TRPV1 TNF TLR4 IL1B

Molecular functions related to Irritable Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.77 TRPV1 TLR4 HTR3A CRHR2 CRHR1
2 cytokine activity GO:0005125 9.73 TNF IL6 IL1B IL10
3 peptide hormone receptor binding GO:0051428 9.4 VIP CCK
4 hormone activity GO:0005179 9.35 VIP PYY MLN CRH CCK
5 serotonin binding GO:0051378 9.33 SLC6A4 HTR4 HTR3A
6 corticotropin-releasing hormone receptor activity GO:0043404 9.32 CRHR2 CRHR1
7 corticotrophin-releasing factor receptor activity GO:0015056 9.26 CRHR2 CRHR1
8 neuropeptide hormone activity GO:0005184 8.92 VIP PYY CRH CCK

Sources for Irritable Bowel Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....